AtriCure, Inc. (ATRC) 株式分析

企業概要

AtriCure, Inc. is a medical technology enterprise focused on the development, manufacturing, and commercialization of devices designed for surgical ablation of cardiac tissue, the exclusion of the left atrial appendage, and the temporary blockade of pain through peripheral nerve ablation. The company operates within the Healthcare sector, specifically in the Medical Instruments & Supplies industry, positioning it as a specialized provider of critical surgical tools to medical centers across the United States, the Asia-Pacific region, and internationally. AtriCure holds a market capitalization of $1.42B and reported annual revenue of $534.53M, while employing a workforce of 1,350 individuals. These valuation and revenue figures indicate that the company is a significant player in its niche, possessing a substantial asset base and a mature operational scale that allows for extensive global distribution of its specialized ablation and exclusion technologies.

財務健全性

AtriCure reported a trailing twelve-month revenue of $534.53M, with a corresponding net income of -$11,448,000 and an EBITDA of $11.08M. The substantial gap between the positive revenue and the negative net income reveals a cost structure where operating expenses, such as research and development or sales costs, significantly exceed operating profits, resulting in an overall loss despite strong top-line performance. The company generated free cash flow of $38.94M, which provides a critical layer of financial flexibility to fund ongoing operations, R&D initiatives, and capital expenditures without relying on external financing. The gross margin stands at 75.0%, indicating highly efficient production costs relative to revenue, whereas the operating margin is a modest 1.8%, suggesting that overhead and indirect costs are consuming a large portion of the gross profit. The profit margin is negative at -2.1%, confirming that the company is currently burning cash on an accrual basis, which is common in growth-stage biotech or medtech firms. On the balance sheet, the company holds $167.43M in cash against $76.42M in debt, resulting in a debt-to-equity ratio of 15.54, which presents a complex picture of high leverage relative to equity but is underpinned by a robust cash reserve. The current ratio of 3.96 indicates strong short-term liquidity, as the company possesses nearly four times the current assets required to cover its current liabilities. Return on equity is -2.4% and return on assets is -0.9%, metrics that reveal that management has not yet generated positive returns on the capital invested in the business, reflecting the challenges of achieving profitability in this sector.

バリュエーション評価

AtriCure does not have a trailing P/E ratio listed, while the forward P/E is 75.89, implying that the market is pricing in significant future earnings growth that is not yet reflected in current profitability. The price-to-book ratio is 2.84, indicating that the market values the company at nearly three times its net asset value, which suggests a premium assigned to its intangible assets, intellectual property, and growth potential. The price-to-sales ratio is 2.66, and the EV/EBITDA is 117.84; these alternative valuation metrics suggest that investors are willing to pay a high multiple for revenue and operating cash flow given the expectation of future margin expansion. The stock has a 52-week high of $43.18 and a 52-week low of $27.27, providing a clear range of historical volatility for the security. Without a specific current share price listed in the facts to calculate the exact percentage, the valuation is anchored by these extremes, showing the stock has experienced significant movement over the past year. The beta value is 1.43, which means the stock's price volatility is 43% higher than the broader market, indicating it is an aggressive position that will likely outperform or underperform the market index with greater intensity during market fluctuations.

Growth & Income

AtriCure achieved a revenue growth rate of 13.1% year-over-year, while earnings growth is not applicable due to the negative net income position. Since earnings are negative, the concept of earnings growing faster or slower than revenue does not apply in the traditional sense, but the top-line expansion demonstrates successful market penetration and product adoption. As a non-dividend payer, the company has a dividend yield of N/A and a payout ratio of 0.0%, indicating that the firm retains all of its earnings to reinvest into research, development, and commercialization efforts rather than distributing cash to shareholders. This reinvestment strategy is typical for companies in the early-to-mid stages of profitability, where capital allocation is prioritized toward sustaining growth trajectories and securing market share in the competitive medical device landscape. The overall growth and income profile is characterized by strong revenue expansion and zero dividend distribution, reflecting a capital-intensive growth model that relies on future profitability to sustain operations.